New study paves the way for precision drugs to treat blood cancers
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain. (Source: World Pharma News)
Source: World Pharma News - April 4, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Association between cancer-related fatigue and falls in patients with myeloproliferative neoplasms: results of a multicenter cross-sectional survey from the East German study group for hematology and oncology (OSHO #97) - Felser S, Gube M, Gruen J, Coutre PI, Schulze S, Muegge LO, Junghanss C, Ulbricht S.
This study retrospectively examined the association between cancer-related fatigue (CrF) and the number of falls during the last 12 months in patients with myeloproliferative neoplasms (MPNs). METHODS: A multicenter, 1-time anonymous s... (Source: SafetyLit)
Source: SafetyLit - December 26, 2022 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Merck to buy Imago BioSciences for $1.35 billion
Imago is developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 21, 2022 Category: Pharmaceuticals Authors: I-Chun Chen Source Type: news
Drugs studied at the Mays Cancer Center help those with bone marrow cancers
Ruben Mesa, MD, FACP executive director of the Mays Cancer Center at UT Health San Antonio, has seen too many patients and families struggle with deadly bone marrow cancers. He is an international expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that often lead to leukemia.
A 25-year trailblazer in MPN research, he led the development of the first U.S. guidelines on diagnosis and treatment of these disorders. He has been principal investigator or co-principal investigator … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 1, 2022 Category: Biotechnology Authors: UT Health San Antonio Source Type: news
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
VONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count
SEATTLE, April 14, 2022 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that VONJO (pa... Biopharmaceuticals, Oncology CTI BioPharma, VONJO , pacritinib, Myeloproliferative Neoplasms, JAK inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 14, 2022 Category: Pharmaceuticals Source Type: news
Mayo Clinic Q and A: Blood disorder causes body to make too many red blood cells
DEAR MAYO CLINIC: I have a relative who was diagnosed with polycythemia vera. What is this disorder, and can it be treated? Is any new research being conducted on polycythemia vera? ANSWER: Polycythemia vera is a blood disorder where the body makes too many red blood cells. It's one in a family of diseases called myeloproliferative disorders. In these diseases, bone marrow — the spongy tissue inside bones where blood cells are made — is affected by… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 11, 2022 Category: Databases & Libraries Source Type: news
Hematoxylin as a killer of CALR mutant cancer cells
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Patients with myeloproliferative neoplasm (MPN) often have a carcinogenic mutated form of the calreticulin gene (CALR). Scientists of the research group of Robert Kralovics, Adjunct Principal Investigator at CeMM and group leader at the Medical University of Vienna, have now identified hematoxylin as a novel CALR inhibitor. The study, published in the renowned journal Blood, shows how hematoxylin compounds affect a specific domain of CALR and selectively kill those CALR mutant cells. The discovery has enormous therapeutic potential and gives ...
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news
Identified the genetic landscape of myelodysplastic/myeloproliferative neoplasms
(Josep Carreras Leukaemia Research Institute) Researchers from the MDS Group of the Josep Carreras Leukaemia Research Institute and the Munich Leukemia Laboratory map the mutations that can ease and accelerate the diagnosis of Myelodysplastic/Myeloproliferative Neoplasms rare malignancies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2020 Category: International Medicine & Public Health Source Type: news
Researchers attempt new treatment approach for blood cancer
(Boston University School of Medicine) In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model. An increase in megakaryocyte numbers is thought to be the cause of many problems observed in this disease. This type of treatment approach has never been attempted before. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 19, 2020 Category: International Medicine & Public Health Source Type: news
Research into rare blood cancers myeloproliferative neoplasms goes...
The Canadian MPN Research Foundation and Ruby Red Research Foundation have joined forces with U.S. based MPN Research Foundation to fund projects in their home countries that will have global impact.(PRWeb December 04, 2019)Read the full story at https://www.prweb.com/releases/research_into_rare_blood_cancers_myeloproliferative_neoplasms_goes_global/prweb16759056.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 4, 2019 Category: Pharmaceuticals Source Type: news
What Are Common Presentations for Budd-Chairi in Adolescents?
Discussion
Budd-Chiari syndrome (BCS) is a rare liver disease caused by hepatic venous outflow obstruction (HVOTO). The obstruction can be anywhere from the small intrahepatic veins up to the inferior vena cava junction with the right atrium. The liver parenchyma itself is not directly affected but becomes compromised because of the increased hepatic sinusoidal pressure over time. The causes include: prothrombic events (35% of cases such as Protein C or Protein S deficiency, Factor V Leiden or antithrombin deficiency), myeloproliferative conditions, oral contraceptive use, and local factors.
BCS can occur in any age but i...
Source: PediatricEducation.org - July 8, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Genetics allows personalized disease predictions for chronic blood cancers
(Wellcome Trust Sanger Institute) Scientists have developed a successful method to make truly personalised predictions of future disease outcomes for patients with certain types of chronic blood cancers. Wellcome Sanger Institute researchers and collaborators combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms. Published in the New England Journal of Medicine, the research identified eight different genetic subgroups of the disease and could lead to personalized medicine for patients with these blood cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2018 Category: Cancer & Oncology Source Type: news
Myelodysplastic Myeloproliferative Leukemia Types
Myelodysplastic or Myeloproliferative Neoplasms (Leukemia Types) (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 27, 2018 Category: General Medicine Source Type: news
JAK1/2 Inhibitors Linked to Lymphoma Risk in Myelofibrosis JAK1/2 Inhibitors Linked to Lymphoma Risk in Myelofibrosis
New data show that the use of JAK1/2 inhibitors, the only FDA-approved therapies for myeloproliferative neoplasms, is associated with a risk for lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Implications of Mutation Profiling in Myeloid Malignancies —PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Douglas Tremblay, MD John O. Mascarenhas, MD Kelsey Sokol, MD Raajit Rampal, MD Sheena Bhalla, MD Tags: Hematologic Malignancies Myeloproliferative Neoplasms Oncology Journal Review Article Source Type: news
